Skip to content

+1 877 566 4981

info@fdamap.com

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us
Contact Us
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us

Day: October 12, 2017

FDA’s “Love”-Less Warning Letter to a Boston Bakery: Food GMP Overkill?

April 9, 2025October 12, 2017 by Prahsant Kumar

Last month FDA sent a Warning Letter citing GMP and labeling violations to a bakery based in the suburbs of Boston which could be perceived by many to be an example of overkill by the Agency auditors, and is some ways it is. The most outrageous statement in the FDA letter was to ding the … Read more

Categories Blog

CTTI Suggests Ways To Reduce “One And Done” Clinical Investigators

April 9, 2025October 12, 2017 by Prahsant Kumar

About half of the physicians who participate in clinical trials do only one trial, never doing another one. About half of the investigators in clinical trials are new, doing their first, and possibly last, clinical trial. Doctors do not do second trials because of the extra work and time needed to conduct a trial and … Read more

Categories Blog

Recent Posts

  • From In silico to In vivo: Orchestrating AI for Breakthrough Therapeutics
  • Navigating the Hallucination Risks of Regulatory AI
  • Beyond the P-Value: Navigating the FDA’s New Bayesian Guidance for Drugs and Biologics
  • The Lean IND: Operationalizing the “Least Burdensome” Mandate
  • Beyond the LAL: Critical Updates to Bacterial Endotoxins and Pyrogen Testing

Recent Comments

No comments to show.

One-stop source for FDA consultation, regulatory affairs training, and clinical trial services.

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin

Services

  • Webinars
  • Workshops
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions

Company

  • About Us
  • Our Client
  • Testimonials
  • Free Resources
  • Newsletter

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy

Payment Method

100% Secure Transaction

Copyright © 2025 FDAMap.com. All rights reserved.